Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy

Leukemia Research

Volumn 36, Issue 2, 2012, Pages 212-218

  Balsas, Patricia ^a   Galán Malo, Patricia ^a   Marzo, Isabel ^a   Naval, Javier ^a  

^a UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

Apoptosis; Histone deacetylase inhibitors; Myeloma; Polyploidy; Proteasome

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; DOXORUBICIN; EPOXOMICIN; MELPHALAN; TRICHOSTATIN A; VINCRISTINE;

ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG SENSITIVITY; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MYELOMA CELL; POLYPLOIDY; PRIORITY JOURNAL; PSM BETA5 GENE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BORONIC ACIDS; CASPASE 3; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MULTIPLE MYELOMA; POLYPLOIDY; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84855204408     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.09.011     Document Type: Article

References (24)

1. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol 2007, 137:429-435.
2. Merchionne F., Perosa F., Dammacco F. New therapies in multiple myeloma. Clin Exp Med 2007, 7:83-97.
3. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352:2487-2498.
4. Kumar S., Rajkumar S.V. Many facets of bortezomib resistance/susceptibility. Blood 2008, 112:2177-2178.
5. Oerlemans R., Franke N.E., Assaraf Y.G., Cloos J., van Zantwijk I., Berkers C.R., et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMβ5) gene mutation and overexpression of PSMβ5 protein. Blood 2008, 112:2489-2499.
6. Ruckrich T., Kraus M., Gogel J., Beck A., Ovaa H., Verdoes M., et al. Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells. Leukemia 2009, 23:1098-1105.
7. Ri M., Iida S., Nakashima T., Miyazaki H., Mori F., Ito A., et al. Bortezomib-resistant myeloma cell lines: a role for mutated PSMβ5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia 2010, 24:1506-1512.
8. Balsas P., Lopez-Royuela N., Galan-Malo P., Anel A., Marzo I., Naval J. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis. Biochem Pharmacol 2009, 77:804-812.
9. Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988, 48:589-601.
10. Millar B.C., Millar J.L., Jones A., Feary S.W., Robertson D., Bell J.B. Activation of murine 'T' lymphomas in the presence of a human myeloma cell line, RPMI-8226, in vivo. Br J Cancer 1988, 57:290-292.
11. Lightcap E.S., McCormack T.A., Pien C.S., Chau V., Adams J., Elliot P.J. Proteasome inhibition measurements: clinical application. Clin Chem 2000, 46:673-683.
12. Lee D.H., Goldberg A.L. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 1998, 8:397-403.
13. Miller C.P., Rudra S., Keating M.J., Wierda W.G., Palladino M., Chandra J. Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells. Blood 2009, 113:4289-4299.
14. Nawrocki S.T., Carew J.S., Maclean K.H., Courage J.F., Huang P., Houghton J.A., et al. Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood 2008, 112:2917-2926.
15. Batty N., Malouf G.G., Issa J.P. Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett 2009, 280:192-200.
16. Naujokat C., Fuchs D., Berges C. Adaptive modification and flexibility of the proteasome system in response to proteasome inhibition. Biochim Biophys Acta 2007, 1773:1389-1397.
17. Lu S., Yang J., Song X., Gong S., Zhou H., Guo L., et al. Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line. J Pharmacol Exp Ther 2008, 326:423-431.
18. Politou M., Karadimitris A., Terpos E., Kotsianidis I., Apperley J.F., Rahemtulla A. No evidence of mutations of the PSMβ5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib. Leuk Res 2006, 30:240-241.
19. Yuan J., Shah R., Kulharya A., Ustun C. Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient. Leuk Res 2010, 34:954-957.
20. Musacchio A., Salmon E.D. The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol 2007, 8:379-393.
21. Kuhn D.J., Chen Q., Voorhees P.M., Strader J.S., Shenk K.D., Sun C.M., et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007, 110:3281-3290.
22. Dick L.R., Fleming P.E. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today 2010, 15:243-249.
23. Richardson P., Mitsiades C., Colson K., Reilly E., McBride L., Chiao J., et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 2008, 49:502-507.
24. Zhang Q.L., Wang L., Zhang Y.W., Jiang X.X., Yang F., Wu W.L., et al. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Leukemia 2009, 23:1507-1514.